KW-8232|cas:217813-15-5|西域试剂

KW-8232,98.02%

产品编号：Bellancom-100304A| CAS NO：217813-15-5| 分子式：C₃₇H₄₁ClN₄O₆S| 分子量：705.26

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-100304A	￥5000.00	杭州北京（现货）
Bellancom-100304A	￥8500.00	杭州北京（现货）
Bellancom-100304A	￥18000.00	杭州北京（现货）
Bellancom-100304A	￥30000.00	杭州北京（现货）
Bellancom-100304A	￥46000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

KW-8232

产品介绍

KW-8232 是一种具有口服活性的抗骨质疏松剂，可以减少前列腺素 PGE2 的生物合成。

生物活性

KW-8232, an orally active anti-osteoporotic agent, and can reduces the biosynthesis of PGE2.

体外研究

KW-8232 is an anti-osteoporotic agent. KW-8232 reduces the biosynthesis of PGE₂ in mouse osteoblastic cells.
KW-8232 possesses anti-viral activity against SARS-CoV-2 (EC₅₀ ~1.2 μM ).

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

KW-8232 (3, 10, 30 mg/kg, p.o.) potently increases the femoral bone mineral density (BMD) of immobilized legs of rats, and affects immobilization-induced abnormal bone turnovrer. KW-8232 markedly decreases urinary calcium excreation in the neurectomized rats only at 30 mg/kg, and highly reduces urinary pyridinoline and deoxypyridionline excretion which are markers of bone resorption in neurectomized rats. KW-8232 inhibits bone loss may be attributed to the lower prostaglandins (PGs)-stimulated bone resorption via regulation of PGE2 production.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	male Sprague-Dawley rats (5-week-old).
Dosage:	1, 3, 10, and 30 mg/kg.
Administration:	Orally once daily beginning 1 day prior to neurectomy for 28 days.
Result:	Decreased urinary calcium excreation in the neurectomized rats only at 30 mg/kg.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	male Sprague-Dawley rats (5-week-old).
Dosage:	1, 3, 10, and 30 mg/kg.
Administration:	Orally once daily beginning 1 day prior to neurectomy for 28 days.
Result:	Decreased urinary calcium excreation in the neurectomized rats only at 30 mg/kg.

性状

Solid

溶解性数据

In Vitro:

DMSO : 125 mg/mL (177.24 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.4179 mL	7.0896 mL	14.1792 mL
5 mM	0.2836 mL	1.4179 mL	2.8358 mL
10 mM	0.1418 mL	0.7090 mL	1.4179 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (2.95 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (2.95 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。